These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36734144)

  • 21. Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice.
    Fuchs J; Chu H; O'Day P; Pyles R; Bourne N; Das SC; Milligan GN; Barrett AD; Partidos CD; Osorio JE
    Vaccine; 2014 Nov; 32(48):6537-43. PubMed ID: 25239488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
    Weiskopf D; Angelo MA; Bangs DJ; Sidney J; Paul S; Peters B; de Silva AD; Lindow JC; Diehl SA; Whitehead S; Durbin A; Kirkpatrick B; Sette A
    J Virol; 2015 Jan; 89(1):120-8. PubMed ID: 25320311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
    Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
    J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.
    Durbin AP
    Curr Opin Virol; 2020 Aug; 43():79-87. PubMed ID: 33164790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
    Metz SW; Thomas A; Brackbill A; Xianwen Y; Stone M; Horvath K; Miley MJ; Luft C; DeSimone JM; Tian S; de Silva AM
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006793. PubMed ID: 30248097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.
    Blaney JE; Sathe NS; Goddard L; Hanson CT; Romero TA; Hanley KA; Murphy BR; Whitehead SS
    Vaccine; 2008 Feb; 26(6):817-28. PubMed ID: 18191005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using recombinant DNA technology for the development of live-attenuated dengue vaccines.
    Lee HC; Butler M; Wu SC
    Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.
    Lindow JC; Durbin AP; Whitehead SS; Pierce KK; Carmolli MP; Kirkpatrick BD
    Vaccine; 2013 Jul; 31(33):3347-52. PubMed ID: 23735680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.
    Lin TH; Chen HW; Hsiao YJ; Yan JY; Chiang CY; Chen MY; Hu HM; Wu SH; Pan CH
    Front Immunol; 2020; 11():546. PubMed ID: 32300346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines.
    Hou J; Ye W; Chen J
    Front Immunol; 2022; 13():840104. PubMed ID: 35281026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice.
    Brewoo JN; Kinney RM; Powell TD; Arguello JJ; Silengo SJ; Partidos CD; Huang CY; Stinchcomb DT; Osorio JE
    Vaccine; 2012 Feb; 30(8):1513-20. PubMed ID: 22178727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tetravalent formulation of polymeric nanoparticle-based vaccine induces a potent immune response against dengue virus.
    Khan RA; Ahmed F; Afroz S; Khan N
    Biomater Sci; 2022 May; 10(11):2917-2928. PubMed ID: 35470821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
    Strouts FR; Popper SJ; Partidos CD; Stinchcomb DT; Osorio JE; Relman DA
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004731. PubMed ID: 27214236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.